United Therapeutics (UTHR) Stock Price

United Therapeutics Corp is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of United Therapeutics Corp in the market include companies like Gilead Sciences Inc., Actelion Pharmaceuticals Ltd., and Bayer AG.

United Therapeutics Corp is a leading biotechnology company specializing in the development of innovative therapies for patients with serious medical conditions. Founded in 1996 by Martine Rothblatt, the company has a rich history of pioneering advancements in the field of pulmonary arterial hypertension (PAH) and other rare diseases. United Therapeutics focuses on the research, development, and commercialization of drugs and devices that address the unmet needs of patients worldwide. With a mission to provide hope and improved quality of life, United Therapeutics Corp has successfully introduced several groundbreaking therapies, establishing itself as a trusted global healthcare provider.

Founded in 1996, United Therapeutics Corp has achieved several significant milestones. The company developed Remodulin®, a treatment for pulmonary arterial hypertension (PAH) that received FDA approval in 2002. In the following years, the company successfully launched Tyvaso® and Adcirca®, adding to their portfolio of PAH therapies. Moreover, United Therapeutics Corp pioneered the development of Ex-vivo Lung Perfusion (EVLP) technology, which improves the quality of donor lungs for transplantation. The company's efforts in advancing PAH treatments and lung transplantation techniques have greatly impacted the medical field, making United Therapeutics Corp a global leader in the pharmaceutical industry.

United Therapeutics Corp is primarily present in the United States.

United Therapeutics Corp is committed to delivering innovative solutions in the field of biotechnology. With a strong emphasis on patient care and well-being, the company strives to improve the lives of individuals suffering from severe medical conditions. United Therapeutics Corp's corporate philosophy revolves around cultivating a culture of excellence, fostering a collaborative approach, and maintaining a steadfast dedication to scientific research and development. By consistently pushing boundaries and working towards groundbreaking advancements, United Therapeutics Corp aims to provide hope and transformative therapies for patients worldwide.

Analysts currently set an average price target of 635.00 USD for the United Therapeutics stock (median: 625.00 USD), implying +17.3 % versus the latest price. The consensus is based on 22 analyst ratings.

United Therapeutics Analyst Price Targets 2026

22 analysts currently rate the United Therapeutics stock: 18 recommend buying, 4 holding and 0 selling. For 2026, analysts expect United Therapeutics to generate revenue of 3.15 B USD and earnings per share of 26.45 USD.

United Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the United Therapeutics share trades at 483.21 EUR (541.33 USD).

The United Therapeutics share (UTHR) is listed on 5 stock exchanges, including: NASDAQ (UTHR), SIX (Zürich) (UTH.SW), Frankfurt (UTH.F), München (UTH.MU), Düsseldorf (UTH.DU).

United Therapeutics Corp is a leading biotechnology company focused on the development and commercialization of innovative therapies for rare and serious diseases. The company has been pursuing a dual-track strategy since its founding in 1996, which includes both the development of novel drugs and the marketing of already approved products. United Therapeutics' core business focuses on developing drugs for the treatment of lung diseases. The company has specialized particularly in pulmonary hypertension, a rare condition in which high blood pressure in the pulmonary arteries leads to narrowing of the blood vessels and can occur especially in young women. Treatment options for pulmonary hypertension have been limited for a long time, but United Therapeutics has made a breakthrough with its various products. One of United Therapeutics' best-known products is Remodulin, an intravenous medication for the treatment of pulmonary arterial hypertension (PAH) that was already approved in 2002. In addition to Remodulin, the company has also introduced Tyvaso, which is administered as a handheld inhaler and offers patients more flexibility in dosage and application. Another product for the treatment of pulmonary hypertension is Orenitram, an oral medication developed for patients who have difficulty using intravenous medications or inhalers. In addition to developing new drugs, United Therapeutics is also working on further developing and improving existing products. An example of this is the implant for partial lung replacement developed by its subsidiary Lung Biotechnology PBC. The implant contains living cells from a donor lung and is implanted into the body to support the function of the heart-lung system and bridge the time until transplantation. Another focus of United Therapeutics is advancing xenotransplantation, in which organs from animals are to be transplanted into humans. The company has already made significant progress in this field and is closely collaborating with other companies and organizations to further improve this technology. Overall, United Therapeutics' business model is focused on long-term growth and the development of innovative therapies. The company invests heavily in research and development and works closely with customers, partners, and other companies to develop groundbreaking solutions for serious and rare diseases. Through its close collaboration with physicians, research institutes, and patient organizations, the company strives to provide patients worldwide with access to life-saving therapies while also providing its shareholders with solid returns.

The expected revenue of United Therapeutics is 3.15 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of United Therapeutics is 1.27 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of United Therapeutics is currently 20.47. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the United Therapeutics stock.

The price-to-sales ratio (P/S) of United Therapeutics is currently 8.24. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the United Therapeutics stock.

The Eulerpool Quality Score for United Therapeutics is 6/10.

The ISIN of United Therapeutics is US91307C1027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of United Therapeutics is 923818. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of United Therapeutics is UTHR. The ticker symbol is used to trade United Therapeutics shares on the stock exchange.